Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.
11 Julho 2023 - 9:00AM
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume
measurement technology, today announces expansion of blood volume
analysis (BVA) into five of six hospitals in the Southeast and
increased utilization for clinical use at two sites to guide fluid
management in patients during the second quarter of 2023. The
recent launch of Daxor’s ezBVA Lab service at quarter-end is
anticipated to contribute significantly to growth of BVA sales,
while providing additional validation for the use of BVA in the
coming quarters based upon the pipeline of leads that have already
expressed interest in the new offering.
A six-facility hospital system currently
operating throughout Northern Kentucky and Southeastern Indiana
with 169 physician specialty and primary care offices has begun
utilizing Daxor’s ezBVA Lab service - a state-of-the-art
CLIA-certified facility located at Daxor’s Oak Ridge facility that
provides on-demand, next day blood volume analysis results for
their heart failure clinic patients. The hospital system is finding
the diagnostic highly effective to optimize care for their heart
failure population and a growing cohort of clinicians are gaining
expertise with BVA technology.
“Expanding commercialization with the addition
of new hospital systems, new treatment areas, and growing clinical
and health economic evidence of the benefit our diagnostic provides
remains one our key priorities,” said Michael Feldschuh, Daxor’s
CEO and President. “The recent launch of our ezBVA Lab service,
which reduces test-related overhead and labor, is expected to
accelerate adoption and enhance greater prescriber access to our
BVA technology in the second half of this year.”
Two additional hospitals have expanded the use
of BVA testing highlighting the importance of BVA use in the
clinical setting. A leading hospital and academic center in New
York, ranked in the top three in the country according to the U.S.
News & World Report’s annual 2022 “Best Hospitals'', has begun
offering the BVA testing to patients with dysautonomia, a group of
medical conditions caused by problems with the autonomic nervous
system of which blood volume derangements are often common and go
undiagnosed. A second top-ranked facility in central Pennsylvania
serving more than one million people through ten hospital campuses,
a health plan with more than half a million members, a research
institute and the College of Health Sciences, has expanded its use
of BVA-100 for its cardiac amyloid patients – a rare condition that
impacts the ability of the heart to function properly causing blood
volume abnormalities that can only be quantified using BVA.
“We have a robust sales pipeline going into the
second half of 2023, fueled by our team of sales and clinical
experts, and customers choosing to use Daxor’s ezBVA Lab service –
which provides a quicker solution to solve the challenges of
hospital readmissions and length of stay without the need for
upfront capital investment. It seamlessly integrates into existing
workflows, and facilitates easier access to BVA,” said Jean Oertel,
Daxor’s Sr. Vice President of Commercialization and Customer
Experience.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the
global leader in blood volume measurement technology focused on
blood volume testing innovation. We developed and market the
BVA-100® (Blood Volume Analyzer), the only diagnostic blood
test cleared by the FDA to provide safe, accurate, objective
quantification of blood volume status and composition compared to
patient-specific norms. Over 65,000+ tests have been performed at
leading hospital centers across the U.S., enhancing hospital
performance metrics in a broad range of surgical and medical
conditions, including significantly reducing mortality and
readmissions in heart failure and critical care. Daxor has several
ongoing multicenter trials in the areas of COVID-19 and heart
failure treatment with support from the NIH and is under contract
developing analyzers to improve combat casualty care with the U.S.
Department of Defense. Daxor's mission is to advance healthcare by
enabling optimal fluid management with blood volume analysis.
Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024